Please login to the form below

Not currently logged in
Email:
Password:

Nikon expands into healthcare and buys retinal tech firm

Japanese camera and technology company spends big on Scotland’s Optos

Eye test Nikon Corporation will pay £259m to obtain full control of Scottish eye specialist firm Optos.

The Fife-based company develops eye testing machines which can detect high blood pressure and a number of cancers. 

Nikon is publically best known for its cameras but as with a number of technology firms, such as Samsung, IBM, Apple and Microsoft, the Japanese company is looking to move into the medical sector. Nikon said in a statement that this was “important for its long-term growth”.

Kazuo Ushida, the president of Nikon, said: “I am pleased to announce this strategically important transaction for Optos and Nikon. I am confident that an Optos/Nikon combination would create a world-class 'retina' player and would significantly benefit our respective stakeholders.

“Together, we will pursue various collaboration opportunities and further expand the medical business in the future.”

Optos' chairman, Dr Peter Fellner, added: “Following the transaction, Optos will become a key part of Nikon's future strategy to develop a global medical business and will continue to provide its market-leading solutions to the patients we serve.

“We are therefore pleased to recommend this acquisition to our shareholders.”

In November last year, Optos reported a rise in sales and profits after installing a record number of new products, with revenue increasing by 7% to $170.6m (£109m) in the year to the end of September. Pre-tax profit tax doubled to $18.5m.

Article by
Ben Adams

5th March 2015

From: Research

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
GK Strategy

GK is award-winning independent communications agency specialising in delivering impactful strategies for clients across the healthcare market....

Latest intelligence

Navigating the antibiotic resistance crisis
Blue Latitude Health speaks to Tara DeBoer, PhD, Postdoctoral Researcher and CEO of BioAmp Diagnostics to explore the antimicrobial resistance crisis, and learn how a simple tool could support physicians...
Combined immunotherapies – potential and pitfalls
‘Combining therapeutic compounds is the first logical step towards better results, namely higher rates of patients responding to treatment, with deeper and more sustained responses’...
Report: Achieving launch excellence in the challenging healthcare markets of today
Our in-depth report is based on original data and expert interviews, which coupled with our own experience, ensures we give you the best recommendations for achieving launch success in challenging...

Infographics